Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential

M. A. Altinoz*, S. Guloksuz, I. Elmaci

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Citations (Web of Science)

Abstract

To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.

Original languageEnglish
Pages (from-to)785-792
Number of pages8
JournalClinical & Translational Oncology
Volume19
Issue number7
DOIs
Publication statusPublished - Jul 2017

Keywords

  • Rabies virus
  • Cancer
  • Spontaneous remission
  • Immunotherapy
  • NERVOUS-SYSTEM
  • GLYCOPROTEIN
  • CLEARANCE
  • DELIVERY
  • RECEPTOR
  • THERAPY
  • SIRNA
  • RVG

Cite this